Description
APENTRAL-C is a fixed-dose combination that offers dual benefits in the management of acid-peptic disorders. Pantoprazole, a proton pump inhibitor, provides potent and long-lasting gastric acid suppression, while Cinitapride, a prokinetic agent, improves gastrointestinal motility. Together, they ensure comprehensive relief from gastroesophageal reflux disease (GERD), dyspepsia, and related conditions.
Pharmacological Action
-
Pantoprazole Sodium (40 mg):
-
Selective proton pump inhibitor (PPI).
-
Irreversibly blocks H⁺/K⁺-ATPase in gastric parietal cells.
-
Reduces gastric acid secretion and promotes mucosal healing.
-
-
Cinitapride Hydrogen Tartrate (3 mg):
-
A prokinetic agent with serotonin (5-HT4 agonist, 5-HT2 antagonist) activity.
-
Enhances gastric emptying and esophageal motility.
-
Reduces reflux episodes and improves postprandial symptoms.
Indications
APENTRAL-C is indicated for
-
Gastroesophageal Reflux Disease (GERD)
-
Non-ulcer dyspepsia
-
Functional dyspepsia with delayed gastric emptying
-
Peptic ulcer disease (adjunct therapy)
-
Gastritis with reflux symptoms
-
Nausea, bloating, and fullness due to gastric stasis
-
-
